Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.
Cottu P, Cheeseman S, Hall P, Wöckel A, Scholz CW, Bria E, Orlandi A, Ribelles N, Vallet M, Niklas N, Hogg C, Aggarwal S, Moreira J, Lucerna M, Collin SM, Logue A, Long GH. Cottu P, et al. Breast Cancer Res Treat. 2024 Oct 20. doi: 10.1007/s10549-024-07506-4. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39427280
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, Escalup L, Desmaris R, Vaflard P, Cottu P, Pierga JY, Bidard FC, Cabel L, Acramel A. De Moura A, et al. Among authors: cottu p. Breast Cancer. 2024 Jul;31(4):572-580. doi: 10.1007/s12282-024-01565-7. Epub 2024 Apr 10. Breast Cancer. 2024. PMID: 38600429 Free PMC article.
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
Vanacker H, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, Arnedos M, Cottu PH, Jacquin JP, Dalenc F, Pinton A, Servant N, Attignon V, Rouleau E, Morel A, Legrand F, Jimenez M, Andre F, Bachelot T. Vanacker H, et al. Br J Cancer. 2024 Mar;130(4):613-619. doi: 10.1038/s41416-023-02549-8. Epub 2024 Jan 5. Br J Cancer. 2024. PMID: 38182687 Free PMC article.
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial.
Giacchetti S, Laas E, Bachelot T, Lemonnier J, André F, Cameron D, Bliss J, Chabaud S, Hardy-Bessard AC, Lacroix-Triki M, Canon JL, Debled M, Campone M, Cottu P, Dalenc F, Ballesta A, Penault-Llorca F, Asselain B, Dumas E, Reyal F, Gougis P, Lévi F, Hamy AS. Giacchetti S, et al. Among authors: cottu p. EBioMedicine. 2024 Jun;104:105141. doi: 10.1016/j.ebiom.2024.105141. Epub 2024 May 7. EBioMedicine. 2024. PMID: 38718683 Free PMC article. Clinical Trial.
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities.
Piffoux M, Jacquemin J, Pétéra M, Durand S, Abila A, Centeno D, Joly C, Lyan B, Martin AL, Everhard S, Boyault S, Pistilli B, Fournier M, Rouanet P, Havas J, Sauterey B, Campone M, Tarpin C, Mouret-Reynier MA, Rigal O, Petit T, Lasset C, Bertaut A, Cottu P, André F, Vaz-Luis I, Pujos-Guillot E, Drouet Y, Trédan O. Piffoux M, et al. Among authors: cottu p. Clin Cancer Res. 2024 Oct 15;30(20):4654-4666. doi: 10.1158/1078-0432.CCR-24-0195. Clin Cancer Res. 2024. PMID: 39106085
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.
Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi MA, Pistilli B, Iyengar NM, Cottu P, Lerebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, André F, Vaz-Luis I, Jones LW. Soldato D, et al. Among authors: cottu p. J Clin Oncol. 2024 Sep 1;42(25):3022-3032. doi: 10.1200/JCO.23.01959. Epub 2024 Jun 5. J Clin Oncol. 2024. PMID: 38838281 Free PMC article.
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Vasseur A, Cabel L, Hego C, Takka W, Trabelsi Grati O, Renouf B, Lerebours F, Loirat D, Brain E, Cottu P, Sablin MP, Pierga JY, Callens C, Renault S, Bidard FC. Vasseur A, et al. Among authors: cottu p. Oncogene. 2024 Apr;43(16):1214-1222. doi: 10.1038/s41388-024-02986-6. Epub 2024 Feb 27. Oncogene. 2024. PMID: 38413796 Free PMC article.
288 results